Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting

Table 3

Summary of base case results.

Treatment scenario		Cost (USD)	Unadjusted life years	QALY	ICER
1	BSC, all	29614	0.48	0.21	––
2	PAC, all	40108	0.88	0.41	53705
4	PEM all	108408	0.98	0.47	Dominated
5	PDL1 + (CPS > 1%): PEM PDL1-: PAC	77359	0.98	0.47	Dominated
3	RAM/PAC all	128775	1.05	0.49	Dominated
6	MSI-H: PEM MSS: PAC	72442	1.05	0.51	325611
7	PDL1 + (CPS > 1%): PEM PDL1-: RAM/PAC	130560	1.09	0.52	Weakly dominated
8	MSI-H: PEM MSS: RAM/PAC	152242	1.2	0.58	1074620